Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamgertamig vs SOC in RRMM
NCT07181239Phase 3Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of gamgertamig in multiple myeloma (MM), sponsored by Keymed Biosciences. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07181239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181239.